The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature

Health Economics

Volumn 10, Issue 7, 2001, Pages 601-615

  Hughes, Dyfrig A ^a   Bagust, Adrian ^a   Haycox, Alan ^a   Walley, Tom ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adherence; Compliance; Cost effectiveness; Pharmacotherapies

Indexed keywords

ACICLOVIR; ALENDRONIC ACID; AMOXICILLIN; BISMUTH SALICYLATE; CALCIUM; CEFTRIAXONE; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ETIDRONIC ACID; GANCICLOVIR; HYDROCHLOROTHIAZIDE; IMIPRAMINE; INTERFERON BETA SERINE; ISOSORBIDE MONONITRATE; METRONIDAZOLE; MEVINOLIN; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; NICOTINE; OMEPRAZOLE; PAROXETINE; PILOCARPINE; PREMPAK; PROTON PUMP INHIBITOR; TETRACYCLINE; TOLTERODINE; UNINDEXED DRUG; WARFARIN;

ANGINA PECTORIS; ARTICLE; BACTERIAL INFECTION; BLADDER DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETIC NEPHROPATHY; DRUG COST; DUODENUM ULCER; ECONOMIC ASPECT; EVALUATION; FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL INFORMATION; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; OPEN ANGLE GLAUCOMA; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACEUTICS; PRIORITY JOURNAL; PUBLISHING; RETINITIS; REVIEW; SATISFACTION; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; THROMBOEMBOLISM; TIME; VIRUS INFECTION;

COST-BENEFIT ANALYSIS; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HUMANS; PATIENT COMPLIANCE; SELF ADMINISTRATION;

EID: 0034777349     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.609     Document Type: Article

References (52)

1. Noncompliance may cause half of antihypertensive drug 'failures'
2. Causes and consequences of oral contraceptive noncompliance
3. Non-compliance in organ transplant recipients
4. Pharmacoeconomic evaluations in the real world. Effectiveness versus efficacy studies
5. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens
6. Erratic patient compliance with prescribed drug regimens: Targets for drug delivery systems
7. Guidance for reporting critical summaries of economic evaluations
8. Cost utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis
9. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy
10. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors
11. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy
12. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: Evaluative study carried out in Spain
13. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori
14. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer
15. Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis
16. Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis
17. The cost effectiveness of azithromycin for chlamydia trachomatis infections in women
18. Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy
19. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria
20. Perimenopausal bone density screening-will it help prevent osteoporosis?
21. Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model
22. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in post-menopausal women with osteoporosis
23. Direct cost of depression: Analysis of treatment costs of paroxetine versus imipramine in Canada
24. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings
25. Economic evaluation of dorzolamide vs. pilocarpine for primary open-angle glaucoma
26. A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients
27. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians smoking cessation counselling
28. The cost-effectiveness of the nicotine transdermal patch for smoking cessation
29. Primary non-compliance with prescribed medication in primary care
30. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
31. Cholesterol-reduction intervention study (CRIS): A randomized trial to assess effectiveness and costs in clinical practice
32. Apparent discontinuation rates in patients prescribed lipid-lowering drugs
33. Persistence of use of lipid-lowering medications: A cross-national study
34. Discontinuation rates of cholesterol-lowering medications: Implications for primary care
35. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data
36. Drug compliance in therapeutic trials: A review
37. Cost-effectiveness comparisons using 'real world' randomized trials: The case of new antidepressant drugs
38. Generalisation from phase III clinical trials: Survival, quality of life, and health economics
39. Pharmacoeconomic evaluation of new treatments: Efficacy versus effectiveness studies?
40. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings?
41. A cost-effectiveness analysis of typhoid fever vaccines in US military personnel
42. Cost-effectiveness of Hepatitis A prevention in France
43. Prevention of chickenpox in reproductive-age women: Cost-effectiveness of routine vaccination of susceptibles
44. Preventive therapy for Tuberculosis in HIV-infected persons
45. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis
46. Underutilization of antihypertensive drugs and associated hospitalization
47. Noncompliance with antihypertensive therapy. Economic consequences
48. Ascertaining how much compliance is enough with outpatient antibiotic regimens
49. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy, for the Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team
50. Achieving and assessing therapeutic coverage